Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.

Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany

Open access
Michaeli, Daniel Tobias, Michaeli, Julia Caroline, Boch, Tobias, Michaeli, Thomas · 2023 · Cardiovascular Drugs and Therapy

Abstract

Purpose: Novel pharmaceutical treatments reducing cardiovascular events in dyslipidaemia patients must demonstrate clinical efficacy and cost-effectiveness to promote long-term adoption by patients, physicians, and insurers. Objective: To assess the cost-effectiveness of statin monotherapy compared to additive lipid-lowering therapies for primary and secondary cardiovascular prevention from the perspective of Germany’s healthcare system. Methods: Transition probabilities and hazard ratios were derived from cardiovascular outcome trials for statin combinations with icosapent ethyl (REDUCE-IT), evolocumab (FOURIER), alirocumab (ODYSSEY), ezetimibe (IMPROVE-IT), and fibrate (ACCORD). Costs and utilities were retrieved from previous literature. The incidence of major adverse cardiovascular events was simulated with a Markov cohort model. The main outcomes were the incremental cost-effectiveness ratios (ICER) per quality adjusted life year (QALY) gained. Results: For primary prevention, the addition of icosapent ethyl to statin generated 0.81 QALY and €14,732 costs (ICER: 18,133), whereas fibrates yielded 0.63 QALY and € − 10,516 costs (ICER: − 16,632). For secondary prevention, the addition of ezetimibe to statin provided 0.61 QALY at savings of € − 5,796 (ICER: − 9,555) and icosapent ethyl yielded 0.99 QALY and €14,333 costs (ICER: 14,485). PCSK9 inhibitors offered 0.55 and 0.87 QALY at costs of €62,722 and €87,002 for evolocumab (ICER: 114,639) and alirocumab (ICER: 100,532), respectively. A 95% probability of cost-effectiveness was surpassed at €20,000 for icosapent ethyl (primary and secondary prevention), €119,000 for alirocumab, and €149,000 for evolocumab. Conclusions: For primary cardiovascular prevention, a combination therapy of icosapent ethyl plus statin is a cost-effective use of resources compared to statin monotherapy. For secondary prevention, icosapent ethyl, ezetimibe, evolocumab, and alirocumab increase patient benefit at different economic costs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s10557-021-07310-y

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Markov model structure of health states and acute cardiovascular events. The Markov model illustrates health states of the stimulated cohort defined as “Alive without CVD”, “Alive with CVD”, and “Death”. In any cycle, individuals were at risk for acute cardiovascular events: myocardial infarct, stroke, coronary revascularization, and unstable angina. CVD cardiovascular disease.
Fig. 1 Markov model structure of health states and acute cardiovascular events. The Markov model illustrates health states of the stimulated cohort defined as “Alive without CVD”, “Alive with CVD”, and “Death”. In any cycle, individuals were at risk for acute cardiovascular events: myocardial infarct, stroke, coronary revascularization, and unstable angina. CVD cardiovascular disease.CC BY · PubMed Central
Fig. 2 Cost-effectiveness plane with efficiency frontier for cholesterol and triglyceride lowering treatment strategies in combination with statin. Results are visualized for primary (A) and secondary cardiovascular prevention (B). All costs are presented in Euros (€) and inflation adjusted to 2021 values. QALYs and costs are displayed per person. Treatment options were categorized in cholesterol lowering (ezetimibe, alirocumab, evolocumab) and triglyceride lowering (icosapent ethyl, fibrate) strategies based on the European Society of Cardiology guidelines [8]. QALY quality-adjusted life year
Fig. 2 Cost-effectiveness plane with efficiency frontier for cholesterol and triglyceride lowering treatment strategies in combination with statin. Results are visualized for primary (A) and secondary cardiovascular prevention (B). All costs are presented in Euros (€) and inflation adjusted to 2021 values. QALYs and costs are displayed per person. Treatment options were categorized in cholesterol lowering (ezetimibe, alirocumab, evolocumab) and triglyceride lowering (icosapent ethyl, fibrate) strategies based on the European Society of Cardiology guidelines [8]. QALY quality-adjusted life yearCC BY · PubMed Central
Fig. 3 Probabilistic sensitivity analysis for cholesterol and triglyceride lowering treatment strategies in combination with statin displayed on a cost-effectiveness plane. Results are visualized for primary (A) and secondary cardiovascular prevention (B). All costs are presented in Euros (€) and were inflation adjusted to 2021 values. The figure displays 1,000 iterations of the conducted probabilistic sensitivity analysis which simultaneously varies input parameters by their confidence intervals and defined distribution presented in Table 1. Treatment options were categorized in cholesterol lowering (ezetimibe, alirocumab, evolocumab) and triglyceride lowering (icosapent ethyl, fibrate) strategies based on the European Society of Cardiology guidelines [8]. QALYs and costs are displayed per person. QALY quality-adjusted life year
Fig. 3 Probabilistic sensitivity analysis for cholesterol and triglyceride lowering treatment strategies in combination with statin displayed on a cost-effectiveness plane. Results are visualized for primary (A) and secondary cardiovascular prevention (B). All costs are presented in Euros (€) and were inflation adjusted to 2021 values. The figure displays 1,000 iterations of the conducted probabilistic sensitivity analysis which simultaneously varies input parameters by their confidence intervals and defined distribution presented in Table 1. Treatment options were categorized in cholesterol lowering (ezetimibe, alirocumab, evolocumab) and triglyceride lowering (icosapent ethyl, fibrate) strategies based on the European Society of Cardiology guidelines [8]. QALYs and costs are displayed per person. QALY quality-adjusted life yearCC BY · PubMed Central
Fig. 4 Cost-effectiveness acceptability curves at different willingness-to-pay thresholds for cholesterol and triglyceride lowering treatment strategies in combination with statin. Results are visualized for primary (A) and secondary cardiovascular prevention (B). All costs are presented in Euros (€) and inflation adjusted to 2021 values. Willingness-to-pay threshold in €/QALY. Dotted lines present the willingness-to-pay threshold at which the probability of cost-effectiveness surpasses 95%. Treatment options were categorized in cholesterol lowering (ezetimibe, alirocumab, evolocumab) and triglyceride lowering (icosapent ethyl, fibrate) strategies based on the European Society of Cardiology guidelines [8]. QALY quality-adjusted life year
Fig. 4 Cost-effectiveness acceptability curves at different willingness-to-pay thresholds for cholesterol and triglyceride lowering treatment strategies in combination with statin. Results are visualized for primary (A) and secondary cardiovascular prevention (B). All costs are presented in Euros (€) and inflation adjusted to 2021 values. Willingness-to-pay threshold in €/QALY. Dotted lines present the willingness-to-pay threshold at which the probability of cost-effectiveness surpasses 95%. Treatment options were categorized in cholesterol lowering (ezetimibe, alirocumab, evolocumab) and triglyceride lowering (icosapent ethyl, fibrate) strategies based on the European Society of Cardiology guidelines [8]. QALY quality-adjusted life yearCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Research works printed but not linked: 1

  1. Kodera S, Morita H, Kiyosue A, Ando J, Komuro I. Cost-effectiveness of statin plus eicosapentaenoic acid combination therapy for cardiovascular disease prevention in Japanese patients with hypercholesterolemia - an analysis based on the Japan Eicosapentaenoic Acid Lipid Intervention Study (JELIS). Circ J Off J Jpn Circ Soc. 2018;82:1076–82.

Cited by

See all 23

Metadata

Authors
Michaeli, D. T., Michaeli, J. C., Boch, T., & Michaeli, T.
Affiliations
  • Heidelberg University (DE)
  • German Cancer Research Center (DE)
Corresponding author
Michaeli, Daniel Tobias
Venue
Cardiovascular Drugs and Therapy
Published
2022-01-11
Volume
37
Issue
4
Pages
683-694
ISSN
  • 0920-3206 (ISSN-L)
  • 1573-7241
OpenAlex
W4205437420
Cited by
23
References
37
Citations by year
2026: 3 · 2025: 8 · 2024: 5 · 2023: 4 · 2022: 3
FWCI
4.78
Type
journal article
Language
en
Open access
Licence
Locations
  • Cardiovascular Drugs and Therapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Medizinische Fakultät Mannheim der Universität Heidelberg
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
Keywords
cost-effectiveness, lipid-lowering therapy, statins, icosapent ethyl, PCSK9 inhibitors, evolocumab, alirocumab, ezetimibe, fibrates, major adverse cardiovascular events, primary prevention, secondary prevention, dyslipidemia, quality-adjusted life years, Markov cohort model
MeSH terms
Ezetimibe, Proprotein Convertase 9, Cardiovascular Diseases, Cost-Benefit Analysis, Humans, Quality-Adjusted Life Years, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany. https://app.cochat.ai/papers/10.1007/s10557-021-07310-y
The paper
Michaeli, D. T., Michaeli, J. C., Boch, T., & Michaeli, T. (2023). Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany. Cardiovascular Drugs and Therapy. https://doi.org/10.1007/s10557-021-07310-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.